Lung cancer is the leading cause of cancer death in the U.S.
| Test Name and Number | Recommended Use | Limitations | Follow Up |
|---|---|---|---|
| CBC with Platelet Count & Automated Differential 0040003 Method: Automated Cell Count with Flow Cell Differential |
General screening for metastases Recommended for disease followup |
||
| Hepatic Function Panel 0020416 Method: Refer to individual components. |
General screening for metastases |
||
| Cytology, Pulmonary 8209702 Method: Routine Cytopathologic Evaluation |
May be used as initial screening test |
Negative screening does not mean cancer is not present |
Bronchial brushings, washings, tissue biopsy (transbronchial and open lung) from site of lung involved |
| Cytology, Bronchoalveolar Lavage, Malignancy 8280005 Method: Routine Cytopathologic Evaluation |
May be used as initial screening test |
Negative screening does not mean cancer is not present |
Bronchial brushings, washings, tissue biopsy (transbronchial and open lung) from site of lung involved |
| EGFR by FISH 0049234 Method: Fluorescence in situ Hybridization |
Predict prognosis in lung cancer |
May be inferior to mutation analysis for prediction of response to EGFR antagonists |
Bronchial brushings, washings, tissue biopsy (transbronchial and open lung) from site of lung involved |
| EGFR Mutation Detection by PCR and Fragment Analysis 2002440 Method: Polymerase Chain Reaction/Fragment Analysis |
Predict prognosis in lung cancer and response to therapy |
||
| Cytokeratin 19 Fragment (CYFRA 21-1), Serum 0081344 Method: Enzyme-linked Immunosorbent Assay |
Predict prognosis in early and late stages of NSCLC |
Not sensitive or specific enough to use in screening Results obtained with different methods or kits cannot be used interchangeably Assay values should not be interpreted as absolute evidence of the presence or absence of malignant disease |
|
| Neuron Specific Enolase 0098198 Method: Enzyme-Linked Immunosorbent Assay |
May be useful to monitor tumor recurrence in SCLC | Not sensitive or specific enough to use in screening; moderate levels found in benign diseases and other cancers Results obtained with different methods or kits cannot be used interchangeably Assay values should not be interpreted as absolute evidence of the presence or absence of malignant disease |
|
| Immunohistochemistry Stain Offering arup005 Method: Immunohistochemistry |
For fixed tissue samples, consultative services as well as immunohistochemical staining for ACTH, Ber-Ep4, BCL-2, CA-125, CD57 (Leu7), CD56, CK5/6, CK7, CK20, TTF-1, CDX2, CEA, D2-40, calretinin, chromogranin A, EGFR, EGFR (H-11), EMA, ERA (moc-31), keratin 903 (HMW), NSE, p16, p21, p27, p53, placental alkaline phosphatase (PLAP), PGP9.5, synaptophysin, and villin are available |